0000000000255836

AUTHOR

Benjamin Krämer

showing 3 related works from this author

Indacaterol Once-Daily Reduces COPD Exacerbations over 52 Weeks of Treatment.

2009

COPDmedicine.medical_specialtybusiness.industryInternal medicinemedicineIndacaterolOnce dailymedicine.diseasebusinessmedicine.drugD102. CHRONIC OBSTRUCTIVE PULMONARY DISEASE PHARMACOTHERAPY
researchProduct

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.

2011

Two, once daily (q.d.) inhaled bronchodilators are available for the treatment of chronic obstructive pulmonary disease (COPD): the β(2)-agonist indacaterol and the anticholinergic tiotropium. This blinded study compared the efficacy of these two agents and assessed their safety and tolerability. Patients with moderate-to-severe COPD were randomised to treatment with indacaterol 150 μg q.d. (n=797) or tiotropium 18 μg q.d. (n=801) for 12 weeks. After 12 weeks, the two treatments had similar overall effects on "trough" (24 h post-dose) forced expiratory volume in 1 s. Indacaterol-treated patients had greater improvements in transition dyspnoea index (TDI) total score (least squares means 2.0…

Pulmonary and Respiratory MedicineSpirometryMalemedicine.drug_classScopolamine DerivativesQuinolonesSeverity of Illness IndexCholinergic AntagonistsDrug Administration ScheduleMedical Recordslaw.inventionPulmonary Disease Chronic ObstructiveRandomized controlled trialDouble-Blind MethodlawAdrenergic beta-2 Receptor AntagonistsForced Expiratory VolumemedicineAnticholinergicHumansTiotropium BromideAdverse effectAgedCOPDmedicine.diagnostic_testbusiness.industryTiotropium bromideMiddle Agedmedicine.diseaserespiratory tract diseasesBronchodilator AgentsTreatment OutcomeTolerabilitySpirometryAnesthesiaIndansIndacaterolFemalebusinessmedicine.drugThe European respiratory journal
researchProduct

Indacaterol Provides Effective Bronchodilation In Patients With Chronic Obstructive Pulmonary Disease Irrespective Of Patient Age (<65 Or e65 Year…

2010

medicine.medical_specialtyPatient agebusiness.industryInternal medicineBronchodilationmedicineCardiologyIndacaterolPulmonary diseaseIn patientbusinessmedicine.drugC41. EMERGING PHARMACOLOGY FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE: MECHANISMS AND OUTCOMES
researchProduct